English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/135763
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

AuthorsOrdóñez, José Luis ; Amaral, Ana Teresa; Herrero-Martín, David; García-Macías, Carmen; Sevillano, Victoria ; San-Segundo, Laura; Fraile, Susana ; Teodosio, Cristina; Tirado, Óscar M.; Mora, Jaume; Álava, Enrique de
KeywordsPDX models
DNA damage
Trabectedin
PARP inhibitor
Ewing sarcoma
Issue Date2015
PublisherImpact Journals
CitationOncotarget 6(22): 18875-18890 (2015)
AbstractRecent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors (PARPinh) in combination with DNA damage repair (DDR) agents. Trabectedin is an antitumoral agent that modulates EWSR1-FLI1 transcriptional functions, causing DNA damage. Interestingly, PARP1 is also a transcriptional regulator of EWSR1-FLI1, and PARPinh disrupts the DDR machinery. Thus, given the impact and apparent specificity of both agents with regard to the DNA damage/DDR system and EWSR1-FLI1 activity in ES, we decided to explore the activity of combining PARPinh and Trabectedin in in vitro and in vivo experiments. The combination of Olaparib and Trabectedin was found to be highly synergistic, inhibiting cell proliferation, inducing apoptosis, and the accumulation of G2/M. The drug combination also enhanced γH2AX intranuclear accumulation as a result of DNA damage induction, DNA fragmentation and global DDR deregulation, while EWSR1-FLI1 target expression remained unaffected. The effect of the drug combination was corroborated in a mouse xenograft model of ES and, more importantly, in two ES patient-derived xenograft (PDX) models in which the tumors showed complete regression. In conclusion, the combination of the two agents leads to a biologically significant deregulation of the DDR machinery that elicits relevant antitumor activity in preclinical models and might represent a promising therapeutic tool that should be further explored for translation to the clinical setting.
DescriptionThis is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al.
Publisher version (URL)http://dx.doi.org/10.18632/oncotarget.4303
URIhttp://hdl.handle.net/10261/135763
DOI10.18632/oncotarget.4303
Identifiersdoi: 10.18632/oncotarget.4303
e-issn: 1949-2553
Appears in Collections:(IBIS) Artículos
(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
Ewing sarcoma to trabectedin.pdf2,54 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.